TTM
$11.72
YoY change
+15.4%
5Y CAGR
+13.7%
Peak year (2017)
$11.94
Latest annual
$11.16
EPS (Diluted) history chart for CME Group (CME) from 2000 to 2025
Latest: $11.16
EPS (Diluted) growth chart for CME Group (CME) from 2000 to 2025
Latest: +15.4%
EPS (Diluted) history table for CME Group (CME) from 2000 to 2025
| 2025 | $11.16 | +15.4% | +$1.49 | ||
| 2024 | $9.67 | +9.1% | +$0.81 | ||
| 2023 | $8.86 | +19.7% | +$1.46 | ||
| 2022 | $7.40 | +1.5% | +$0.11 | ||
| 2021 | $7.29 | +24.2% | +$1.42 | ||
| 2020 | $5.87 | -0.7% | −$0.04 | ||
| 2019 | $5.91 | +3.5% | +$0.20 | ||
| 2018 | $5.71 | -52.2% | −$6.23 | ||
| 2017 | $11.94 | +163.6% | +$7.41 | ||
| 2016 | $4.53 | +22.8% | +$0.84 | ||
| 2015 | $3.69 | +10.1% | +$0.34 | ||
| 2014 | $3.35 | +14.7% | +$0.43 | ||
| 2013 | $2.92 | +8.1% | +$0.22 | ||
| 2012 | $2.70 | -50.3% | −$2.73 | ||
| 2011 | $5.43 | +89.9% | +$2.57 | ||
| 2010 | $2.86 | +15.3% | +$0.38 | ||
| 2009 | $2.48 | +2.1% | +$0.05 | ||
| 2008 | $2.43 | -18.7% | −$0.56 | ||
| 2007 | $2.99 | +28.9% | +$0.67 | ||
| 2006 | $2.32 | +31.8% | +$0.56 | ||
| 2005 | $1.76 | +37.5% | +$0.48 | ||
| 2004 | $1.28 | +77.8% | +$0.56 | ||
| 2003 | $0.72 | +14.3% | +$0.09 | ||
| 2002 | $0.63 | +34.0% | +$0.16 | ||
| 2001 | $0.47 | -1243.6% | +$0.51 | ||
| 2000 | −$0.04 | — | — |
- 2025$11.16+15.4%
- 2024$9.67+9.1%
- 2023$8.86+19.7%
- 2022$7.40+1.5%
- 2021$7.29+24.2%
- 2020$5.87-0.7%
- 2019$5.91+3.5%
- 2018$5.71-52.2%
- 2017$11.94+163.6%
- 2016$4.53+22.8%
- 2015$3.69+10.1%
- 2014$3.35+14.7%
- 2013$2.92+8.1%
- 2012$2.70-50.3%
- 2011$5.43+89.9%
- 2010$2.86+15.3%
- 2009$2.48+2.1%
- 2008$2.43-18.7%
- 2007$2.99+28.9%
- 2006$2.32+31.8%
- 2005$1.76+37.5%
- 2004$1.28+77.8%
- 2003$0.72+14.3%
- 2002$0.63+34.0%
- 2001$0.47-1243.6%
- 2000−$0.04—
EPS (Diluted) values are taken from CME Group's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EPS (Diluted) at CME Group (CME)
According to CME Group's latest reported financial statements, the company's current diluted EPS (TTM) is $11.72. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
CME Group (CME) most recent annual diluted EPS stands at $11.16 (2025) – grew 15.4% year-over-year.
CME Group diluted EPS compound annual growth for the 2020–2025 (5 years) window is +13.7%, sustaining 5 straight years of year-over-year growth.
CME Group diluted EPS declined from $11.94 in 2017 to $11.16 in 2025, a 6.5% drawdown.
The highest annual diluted EPS of $11.94 was reported in 2017. The lowest in the available history was −$0.04 in 2000.
CME Group EPS (Diluted) by Year
CME Group EPS (Diluted) 2025: $11.16
2025's diluted EPS for CME Group came in at $11.16, grew 15.4% from 2024.
CME Group EPS (Diluted) 2024: $9.67
CME Group posted diluted EPS of $9.67 in 2024, grew 9.1% from 2023.
CME Group EPS (Diluted) 2023: $8.86
In 2023, CME Group reported diluted EPS of $8.86, grew 19.7% from 2022.
CME Group EPS (Diluted) 2022: $7.40
CME Group diluted EPS in 2022 was $7.40, edged up 1.5% from 2021.
CME Group EPS (Diluted) 2021: $7.29
CME Group diluted EPS in 2021 was $7.29.
See more financial history for CME Group (CME). Or calculate EPS yourself.
Sector peers by EPS (Diluted)
Financial Services peers of CME Group (CME), ranked by their latest diluted EPS
| $51.32 | |
| $31.04 | |
| $20.05 | |
| $16.52 | |
| $10.20 | |
| $10.20 | |
| $6.32 | |
| $3.82 |
- $51.32
- $20.05
- $16.52
- $10.20
- $10.20
- $6.32
Frequently asked questions
CME Group (CME) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation